Prolific Stem Cell and Cell Therapy Blogger Alexey Bersenev (@cells_nnm on Twitter) has recently written a post on his Cell Trials blog titled "Trends in cell therapy clinical trials 2011 – 2013". If you are interested in Stem Cells and Cell Therapy, it is highly likely that you already know Alexey. He is one of the most passionate and dedicated technologists in the area. If you don't know him,... Read More
RoosterBio is introducing a new product for highly efficient bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs) that we are calling RoosterReplenish-MSC. This innovative, first-in-class stem cell product is a concentrated bioreactor feed that replaces nutrients and growth factors that have been depleted during microcarrier expansion of hMSCs and replaces the need for a media exchange, enabling scalable and efficient fed-batch hMSC bioreactor expansion processes. This is the first of several new products that we will launch enabling a cell therapy and tissue engineering bioprocess revolution that will be the foundation of a sustainable Regenerative Medicine Industry. Read More
Human mesenchymal stem cells (hMSC) are currently in use in over 400 clinical trials and are critical components of tomorrow’s cell-based products and devices (1, 2, 3). Secretion of biomolecules by hMSC influences many biological processes and is thought to be central to the mechanism of action. Since widespread clinical use of hMSC and cell-based therapies with positive economic outcomes will be facilitated by frozen storage, cryopreserved hMSC must maintain high levels of biological function upon thaw. Additionally, while hMSC have an excellent clinical track record in terms of safety, efficacy data has been difficult to come by, suggesting that more standardized cell formats are needed. This too could be addressed by effective means of cryopreservation, allowing off-the-shelf hMSC products to be widely used in Regenerative Medicine, Tissue Engineering and for 3D BioPrinting of cells and tissues. Read More
MSC 2015is quickly approaching next month and we at RoosterBio are getting ready. This conference is arguably the single most important conference related to MSCs, and Cleveland is the considered by many to be the birthplace of the current paradigm of MSCs used in therapeutic contexts. We will be sending most of our company, and we do look forward to seeing everyone there. Not only is this...
Read More
INTRODUCTION:

 

Human Mesenchymal Stem/Stromal Cells, or hMSC, are key components of future therapeutics, engineered tissues, and medical devices and are currently in use in over 400 clinical trials (1). Bone marrow-derived MSC (hBM-MSC) have historically been the most widely used hMSC, but hMSC can be isolated from many tissues of the body including fat, umbilical cord blood, dental pulp, Wharton’s...
Read More
We are always looking for ways to enable the commercialization of Cell-based Therapies and Technologies. The ultimate success of the field is dependent on the convergence of several technology fields, and one that isn't given sufficient attention is the Measurement Sciences (or metrology). The National Institute of Standards and Technology (NIST) has a Biosystems and Biomaterials Divisionthat... Read More

RoosterBio participated in the annual Tissue Engineering and Regenerative Medicine International Society’s Annual Meeting of the Americas chapter (or TERMIS-AM for short) in Dec 2014. You can find a lot of content on the meeting at the conference website where you can download the program for free, as well as read the published abstracts in the journal Tissue Engineering. The final registration...
Read More
<table class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td style="text-align: center;"><a href="http://3.bp.blogspot.com/-jfbWgrplfaU/VFuS4CaFc-I/AAAAAAAADIA/LdW1wE6PyeE/s1600/Misconceptions.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img src="http://3.bp.blogspot.com/-jfbWgrplfaU/VFuS4CaFc-I/AAAAAAAADIA/LdW1wE6PyeE/s1600/Misconceptions.jpg" height="188" border="0" width="200" /></a></td>
</tr>
<tr>
<td class="tr-caption" style="text-align: center;"> http://andreyev.com.au/wp-content/uploads/Misconceptions.jpg</td>
</tr>
</tbody>
</table>
<div class="MsoListParagraphCxSpFirst" style="margin-left: 0in; mso-add-space: auto;"><span style="font-family: 'Arial',sans-serif;">We blogged recently about </span><a href="http://roosterbio.blogspot.com/2014/10/current-bottlenecks-in-msc-research.html"><span style="font-family: 'Arial',sans-serif;">Mesenchymal Stem/Stromal Cell (MSC) Misconceptions</span></a><span style="font-family: 'Arial',sans-serif;"> that are holding the translational cell therapy field back, as identified by </span><a href="http://www.scripps.edu/florida/philanthropy/action/phinney-profile.html"><span style="font-family: 'Arial',sans-serif;">Donald Phinney</span></a><span style="font-family: 'Arial',sans-serif;"> and </span><a href="http://www.stromalab.fr/index.php?option=com_content&amp;view=article&amp;id=86&amp;lang=en"><span style="font-family: 'Arial',sans-serif;">Luc Sensebé</span></a><span style="font-family: 'Arial',sans-serif;">. Since we have come to market with our own hMSC product lines, we have spoken with hundreds of MSC researchers and engineers, and we have compiled our own...</span></div> Read More

We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cellsthat are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in...
Read More
Last week was the 4th Annual IBC Cell Therapy Bioprocessing Conference. IBC (home of the BioProcess International conference) was the first conference organizer to dedicate a focused meeting on Cell Therapy Manufacturing Technologies 4 years ago. Since the first conference in 2011, the growth in the field, and the conference, has been amazing. The attendance has grown from less than 90 in year 1...
Read More
1 2 3 Next »